NCT02439138View on ClinicalTrials.gov

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

PHASE2TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Waldenstrom's Macroglobulinemia

Interventions

DRUG

GS-1101

Oral twice daily for 6 months followed by once daily until disease progression or unacceptable toxicity.

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER